company background image
LOGC

LogicBio TherapeuticsNasdaqGM:LOGC Stock Report

Market Cap

US$100.7m

7D

3.6%

1Y

-58.1%

Updated

07 Dec, 2021

Data

Company Financials +
LOGC fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

LOGC Stock Overview

LogicBio Therapeutics, Inc., a genome editing company, focuses on developing medicines to treat rare diseases in patients with unmet medical need using GeneRide technology platform.

Price History & Performance

Summary of all time highs, changes and price drops for LogicBio Therapeutics
Historical stock prices
Current Share PriceUS$3.06
52 Week HighUS$9.75
52 Week LowUS$2.75
Beta1.04
1 Month Change-18.53%
3 Month Change-36.62%
1 Year Change-58.09%
3 Year Change-79.63%
5 Year Changen/a
Change since IPO-73.43%

Recent News & Updates

Aug 18
Does LogicBio Therapeutics (NASDAQ:LOGC) Have A Healthy Balance Sheet?

Does LogicBio Therapeutics (NASDAQ:LOGC) Have A Healthy Balance Sheet?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...

Shareholder Returns

LOGCUS BiotechsUS Market
7D3.6%-7.0%-2.6%
1Y-58.1%-3.7%17.8%

Return vs Industry: LOGC underperformed the US Biotechs industry which returned -1.4% over the past year.

Return vs Market: LOGC underperformed the US Market which returned 16.5% over the past year.

Price Volatility

Is LOGC's price volatile compared to industry and market?
LOGC volatility
LOGC Average Weekly Movement9.5%
Biotechs Industry Average Movement8.9%
Market Average Movement6.2%
10% most volatile stocks in US Market14.8%
10% least volatile stocks in US Market2.4%

Stable Share Price: LOGC is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: LOGC's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
201439Fred Chereauhttps://www.logicbio.com

LogicBio Therapeutics, Inc., a genome editing company, focuses on developing medicines to treat rare diseases in patients with unmet medical need using GeneRide technology platform. The GeneRide technology is designed to integrate corrective genes into a patient's genome to provide a therapeutic effect. The company’s lead product candidate is LB-001 that is in Phase I/II clinical trials for the treatment of methylmalonic acidemia.

LogicBio Therapeutics Fundamentals Summary

How do LogicBio Therapeutics's earnings and revenue compare to its market cap?
LOGC fundamental statistics
Market CapUS$100.68m
Earnings (TTM)-US$37.87m
Revenue (TTM)US$3.93m

25.7x

P/S Ratio

-2.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
LOGC income statement (TTM)
RevenueUS$3.93m
Cost of RevenueUS$0
Gross ProfitUS$3.93m
ExpensesUS$41.79m
Earnings-US$37.87m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-1.15
Gross Margin100.00%
Net Profit Margin-964.74%
Debt/Equity Ratio23.4%

How did LOGC perform over the long term?

See historical performance and comparison

Valuation

Is LogicBio Therapeutics undervalued compared to its fair value and its price relative to the market?

2.6x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate LOGC's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate LOGC's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: LOGC is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: LOGC is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate LOGC's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: LOGC's PB Ratio (2.6x) is in line with the US Biotechs industry average.


Future Growth

How is LogicBio Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

14.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: LOGC is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: LOGC is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: LOGC is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: LOGC's revenue (75.4% per year) is forecast to grow faster than the US market (9.8% per year).

High Growth Revenue: LOGC's revenue (75.4% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if LOGC's Return on Equity is forecast to be high in 3 years time


Past Performance

How has LogicBio Therapeutics performed over the past 5 years?

-32.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: LOGC is currently unprofitable.

Growing Profit Margin: LOGC is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: LOGC is unprofitable, and losses have increased over the past 5 years at a rate of 32% per year.

Accelerating Growth: Unable to compare LOGC's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: LOGC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (11%).


Return on Equity

High ROE: LOGC has a negative Return on Equity (-97.68%), as it is currently unprofitable.


Financial Health

How is LogicBio Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: LOGC's short term assets ($60.7M) exceed its short term liabilities ($13.7M).

Long Term Liabilities: LOGC's short term assets ($60.7M) exceed its long term liabilities ($15.7M).


Debt to Equity History and Analysis

Debt Level: LOGC has more cash than its total debt.

Reducing Debt: Insufficient data to determine if LOGC's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: LOGC has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: LOGC has sufficient cash runway for 1.3 years if free cash flow continues to reduce at historical rates of 27% each year.


Dividend

What is LogicBio Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate LOGC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate LOGC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if LOGC's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if LOGC's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of LOGC's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.0yrs

Average management tenure


CEO

Fred Chereau (54 yo)

5.67yrs

Tenure

US$1,857,535

Compensation

Mr. Frederic Chereau, also known as Fred, M.B.A., is the President and Chief Executive Officer of LogicBio Therapeutics, Inc. since April 2016 and serves as its Director. He serves as Non-Executive Directo...


CEO Compensation Analysis

Compensation vs Market: Fred's total compensation ($USD1.86M) is above average for companies of similar size in the US market ($USD567.11K).

Compensation vs Earnings: Fred's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: LOGC's management team is not considered experienced ( 1 years average tenure), which suggests a new team.


Board Members

Experienced Board: LOGC's board of directors are considered experienced (3.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 3.7%.


Top Shareholders

Company Information

LogicBio Therapeutics, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: LogicBio Therapeutics, Inc.
  • Ticker: LOGC
  • Exchange: NasdaqGM
  • Founded: 2014
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$100.683m
  • Shares outstanding: 32.96m
  • Website: https://www.logicbio.com

Number of Employees


Location

  • LogicBio Therapeutics, Inc.
  • 65 Hayden Avenue
  • 2nd Floor
  • Lexington
  • Massachusetts
  • 2421
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/12/07 00:35
End of Day Share Price2021/12/06 00:00
Earnings2021/09/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.